The Claim
In stop-screen breast cancer screening trials, the fraction of indolent tumors cannot be precisely estimated from grouped screening data alone, even when using a mixture model that accounts for both progressive and nonprogressive lesions, because the data lack sufficient information to constrain the parameter estimates within clinically meaningful ranges.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When doctors stop screening for breast cancer, they can't tell exactly how many of the tumors found would never have caused harm, even with fancy math, because the data they have just isn't detailed enough to give clear answers.
See the scientific wording
In stop-screen breast cancer screening trials, the fraction of indolent tumors cannot be precisely estimated from grouped screening data alone, even when using a mixture model that accounts for both progressive and nonprogressive lesions, because the data lack sufficient information to constrain the parameter estimates within clinically meaningful ranges.
What the research says
1 studyThis study looked at breast cancer screening data and found that even with the best math models, we can't tell exactly how many tumors would never cause harm unless we follow patients longer after screening. This matches the claim that the data alone aren't enough to know the truth.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.